Skip to contentO
Opus Genetics, Inc.
O
IRDOpus Genetics, Inc. Q2 2024 · 10-Q
Revenue$1.11M$1.11M−69.7% vs Q2 2023 Net Income-$7.77M-$7.77MN/M vs Q2 2023 EPS Diluted-$0.30-$0.30N/M vs Q2 2023 Operating Income-$8,328,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Opus Genetics, Inc. · CIK 1228627 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-748.9%−602.2 pt vs Q2 2023
Net margin-698.3%−563.3 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 13, 2024 · 44 d after period end